Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment

doi:10.1073/pnas.1301816110

Table 1.

Demographics and plasma measures at baseline for subjects undergoing the FSL-VBM analysis

Variable	Placebo (n = 76)	B vitamins (n = 80)	P value
Age, y	76 ± 4	77 ± 5	0.10
Sex, F/M	49/27	47/33	0.47
Time between scans, d	744 ± 24	740 ± 25	0.26
Education, y	14.5 ± 3	14.5 ± 3.5	0.47
ApoE: ε4/no ε4	25/51	20/60	0.30
Baseline plasma levels
Vitamin B6, µmol/L	84 ± 28	86 ± 40	0.70
Folate, nmol/L	29 ± 18	29 ± 18	0.54
Vitamin B12, pmol/L	347 ± 99	356 ± 167	0.68
tHcy, µmol/L	11.4 ± 3.1	11.8 ± 3.6	0.47
Creatinine, µmol/L	96 ± 17	96 ± 18	0.97
Baseline cognitive scores
CDR-SOB	1.1 ± 0.7	1.1 ± 0.7	0.85
MMSE	28.5 ± 1.5	28.5 ± 1.5	0.75
HVLT-R (delayed recall)	7.3 ± 3.1	8.1 ± 2.8	0.09
Category fluency (animals)	20.3 ± 4.8	20.4 ± 5.0	0.89

ApoE, apolipoprotein E; CDR-SOB, clinical dementia rating, sum of boxes; MMSE, Mini-mental state examination; HVLT-R, Hopkins verbal learning test, revised. Unless otherwise defined, values are mean ± SD.